Antibody Drug Conjugate Market Opportunity Analysis
Please note: extra shipping charges are applied when purchasing Hard Copy License depending on the location.
Ever since the first attempt in the 1980s to use antibody based drugs as therapeutic agents, the application and use of monoclonal antibody-drug conjugates has evolved in several ways. The major advantage of using Antibody Drug Conjugates (ADC) is that it brings together the best characteristics of both antibodies and the cytotoxic potential of chemotherapy. This offers significant opportunity for the future in terms of targeted accumulation of drug in the tumor cell or tissue.
The Antibody Drug Conjugates has evolved into a special therapeutic class of drugs which can now save patients who suffer from those diseases for which there was no adequate treatment previously. However, one of the major challenges is that the treatment with antibody drugs is highly expensive. From a medical economic perspective, it is most likely that the cost versus value ratio would weigh very high in the future. In order to improve this, it is important that the reliable efficiency of the drugs be proved. Hence, the current market is witnessing an increasing number of pharma companies increasingly focusing their efforts into this field.
With the approvals of brentuximab vedotin(Adcetris) and ado-trastuzumab emtansine (Kadcyla), and more than 100 ADCs in the clinical trial pipeline, the market for this therapeutic class is expected to grow significantly in the future years. It is most likely that the global ADC market would grow at a CAGR of more than 40% to reach USD 6.8 billion by 2020. The other major drivers of the ADC market include the technological advances made in the linker technology and patent fencing. Also, with the entry of large number of companies into this segment, it is likely that competition levels would increase significantly, which would in turn lead to high demand and market value in the years to come.
The Antibody Drug Conjugates market will definitely witness an increase in the partnership and collaborative agreements to develop these drugs. It has been observed that the process of drug development is highly correlated to basic research in Biology and Medicine. Specifically, the details about target molecules and their functions along with their involvement in pathology generally stem from basic research which is conducted in universities and public research institutes. The recent years have thus witnessed a growing relationship between the pharma companies and the academic institutions. Majority of the pharmaceutical companies across the globe have been reducing the size of their departments for basic research. Instead they have started to depend heavily on venture companies and universities, which act as the major source of knowledge.
“Antibody Drug Conjugate Market Opportunity Analysis” Report Highlights:
Ever since the first attempt in the 1980s to use antibody based drugs as therapeutic agents, the application and use of monoclonal antibody-drug conjugates has evolved in several ways. The major advantage of using Antibody Drug Conjugates (ADC) is that it brings together the best characteristics of both antibodies and the cytotoxic potential of chemotherapy. This offers significant opportunity for the future in terms of targeted accumulation of drug in the tumor cell or tissue.
The Antibody Drug Conjugates has evolved into a special therapeutic class of drugs which can now save patients who suffer from those diseases for which there was no adequate treatment previously. However, one of the major challenges is that the treatment with antibody drugs is highly expensive. From a medical economic perspective, it is most likely that the cost versus value ratio would weigh very high in the future. In order to improve this, it is important that the reliable efficiency of the drugs be proved. Hence, the current market is witnessing an increasing number of pharma companies increasingly focusing their efforts into this field.
With the approvals of brentuximab vedotin(Adcetris) and ado-trastuzumab emtansine (Kadcyla), and more than 100 ADCs in the clinical trial pipeline, the market for this therapeutic class is expected to grow significantly in the future years. It is most likely that the global ADC market would grow at a CAGR of more than 40% to reach USD 6.8 billion by 2020. The other major drivers of the ADC market include the technological advances made in the linker technology and patent fencing. Also, with the entry of large number of companies into this segment, it is likely that competition levels would increase significantly, which would in turn lead to high demand and market value in the years to come.
The Antibody Drug Conjugates market will definitely witness an increase in the partnership and collaborative agreements to develop these drugs. It has been observed that the process of drug development is highly correlated to basic research in Biology and Medicine. Specifically, the details about target molecules and their functions along with their involvement in pathology generally stem from basic research which is conducted in universities and public research institutes. The recent years have thus witnessed a growing relationship between the pharma companies and the academic institutions. Majority of the pharmaceutical companies across the globe have been reducing the size of their departments for basic research. Instead they have started to depend heavily on venture companies and universities, which act as the major source of knowledge.
“Antibody Drug Conjugate Market Opportunity Analysis” Report Highlights:
- Global ADC Market Insight
- ADC Patent Analysis
- Orphan Status & ADC
- Favorable Market Drivers & Key Issues to be Discussed
- ADC Clinical Trial Insight by Phase & Target Indications
- ADC Profiles in Report: 201
- Majority of ADC in Preclinical Phase: 83
- Marketed ADC Clinical Profiles
1. INTRODUCTION TO ANTIBODY DRUG CONJUGATE
2. ANTIBODY DRUG CONJUGATE MECHANISM
2.1 Components of Antibody Drug Conjugate
2.2 Mechanism of Antibody Drug Conjugate
3. WHY NEED FOR ANTIBODY DRUG CONJUGATE?
4. ANTIBODY DRUG CONJUGATE MARKET OUTLOOK
4.1 Market Overview
4.2 Anti Drug Conjugate Clinical Pipeline Analysis
5. ANTIBODY DRUG CONJUGATE MARKET DYNAMICS
5.1 Market Acceptability Drivers
5.2 Issues to be Addressed
5.3 Future Growth Opportunities
6. ANTIBODY DRUG CONJUGATE CLINICAL TRIAL INSIGHT BY PHASE & TARGET INDICATIONS
6.1 Research
6.2 Preclinical
6.3 Phase I
6.4 Phase I/II
6.5 Phase II
6.6 Phase II/III
6.7 Phase III
7. MARKETED ANTIBODY DRUG CONJUGATE
8. COMPETITIVE LANDSCAPE
8.1 ADC Therapeutics
8.2 Agensys
8.3 Ambrx
8.4 Amgen
8.5 AREVA Med
8.6 Bayer HealthCare
8.7 Genentech
8.8 Immunomedics
8.9 ImmunoGen
8.10 Seattle Genetics
2. ANTIBODY DRUG CONJUGATE MECHANISM
2.1 Components of Antibody Drug Conjugate
2.2 Mechanism of Antibody Drug Conjugate
3. WHY NEED FOR ANTIBODY DRUG CONJUGATE?
4. ANTIBODY DRUG CONJUGATE MARKET OUTLOOK
4.1 Market Overview
4.2 Anti Drug Conjugate Clinical Pipeline Analysis
5. ANTIBODY DRUG CONJUGATE MARKET DYNAMICS
5.1 Market Acceptability Drivers
5.2 Issues to be Addressed
5.3 Future Growth Opportunities
6. ANTIBODY DRUG CONJUGATE CLINICAL TRIAL INSIGHT BY PHASE & TARGET INDICATIONS
6.1 Research
6.2 Preclinical
6.3 Phase I
6.4 Phase I/II
6.5 Phase II
6.6 Phase II/III
6.7 Phase III
7. MARKETED ANTIBODY DRUG CONJUGATE
8. COMPETITIVE LANDSCAPE
8.1 ADC Therapeutics
8.2 Agensys
8.3 Ambrx
8.4 Amgen
8.5 AREVA Med
8.6 Bayer HealthCare
8.7 Genentech
8.8 Immunomedics
8.9 ImmunoGen
8.10 Seattle Genetics
LIST OF FIGURES
Figure 2-1: Components of Antibody Drug Conjugate
Figure 2-2: Mechanism of Antibody Drug Conjugate
Figure 4-1: Global Antibody Drug Conjugate Market (US$ Billion), 2013-2020
Figure 4-2: Global Adcetris Sales (Million US$), 2013 & 2020
Figure 4-3: Adcetris Sales in US & Europe (Million US$), 2013
Figure 4-4: Global Kadcyla Sales (Million US$), 2013 & 2020
Figure 4-5: Kadcyla Market in US & Ex US (Million US$), 2013
Figure 4-6: Antibody Drug Conjugate Clinical Pipeline by Phase (%)
Figure 4-7: Antibody Drug Conjugate Clinical Pipeline by Phase (%)
Figure 2-1: Components of Antibody Drug Conjugate
Figure 2-2: Mechanism of Antibody Drug Conjugate
Figure 4-1: Global Antibody Drug Conjugate Market (US$ Billion), 2013-2020
Figure 4-2: Global Adcetris Sales (Million US$), 2013 & 2020
Figure 4-3: Adcetris Sales in US & Europe (Million US$), 2013
Figure 4-4: Global Kadcyla Sales (Million US$), 2013 & 2020
Figure 4-5: Kadcyla Market in US & Ex US (Million US$), 2013
Figure 4-6: Antibody Drug Conjugate Clinical Pipeline by Phase (%)
Figure 4-7: Antibody Drug Conjugate Clinical Pipeline by Phase (%)
LIST OF TABLES
Table 8-1: ADC Therapeutics Clinical Pipeline
Table 8-2: Agensys Clinical Pipeline
Table 8-3: Ambrx Clinical Pipeline
Table 8-4: Amgen Clinical Pipeline
Table 8-5: AREVA Med Clincal Pipeline
Table 8-6: Genentech Clinical Pipeline
Table 8-7: Immunomedics Clinical Pipeline
Table 8-8: ImmunoGen Clinical Pipeline
Table 8-9: Seattle Genetics Clinical Pipeline
Table 8-1: ADC Therapeutics Clinical Pipeline
Table 8-2: Agensys Clinical Pipeline
Table 8-3: Ambrx Clinical Pipeline
Table 8-4: Amgen Clinical Pipeline
Table 8-5: AREVA Med Clincal Pipeline
Table 8-6: Genentech Clinical Pipeline
Table 8-7: Immunomedics Clinical Pipeline
Table 8-8: ImmunoGen Clinical Pipeline
Table 8-9: Seattle Genetics Clinical Pipeline
